Acetazolamide for Treatment Resistant Schizophrenia

• Status: Not yet recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vishwajit Nimgaonkar, MD PhD
• Collaborator: Stanley Medical Research Institute
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• Written informed consent.

• Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).

• PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.

• Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.

• Not participating in another randomized controlled clinical trial (RCT).

Exclusion Criteria:

• Substance abuse in the past month/dependence past 6 months, (except nicotine).

• History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.

• Pregnancy.

• Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.

• Current or prior treatment with ACZ or history of hypersensitivity to ACZ.

• Intellectual disability as defined in DSM 5.